STOCK TITAN

[Form 4] PAVmed Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

PAVmed Inc. (PAVM) reporting person Dennis M. McGrath, who is identified as President and CFO, received a grant of 150,000 shares of restricted common stock on 09/30/2025. The shares were granted under the company's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan and carry a single vesting date of May 20, 2028; they are subject to forfeiture if the required service period is not completed. The Form 4 shows 200,834 shares beneficially owned by the reporting person after the transaction. The reported transaction lists a price of $0, indicating these were restricted shares rather than a cash purchase. The filing was executed by power of attorney and dated 10/02/2025.

PAVmed Inc. (PAVM) persona di riferimento Dennis M. McGrath, identificato come Presidente e CFO, ha ricevuto una concessione di 150.000 azioni ordinarie restritte in data 30/09/2025. Le azioni sono concesse ai sensi del Piano di Incentivi a Lungo Termine 2014, Sesto Emendamento e Restatement e hanno una data di vesting unica 20 maggio 2028; sono soggette a perdita se il periodo di servizio richiesto non è completato. Il Form 4 mostra 200.834 azioni detenute economicamente dal soggetto riportante dopo la transazione. La transazione riportata indica un prezzo di $0, il che implica che si trattava di azioni restritte anziché di un acquisto in contanti. Il deposito è stato eseguito per procura e datato 02/10/2025.

PAVmed Inc. (PAVM) persona reportante Dennis M. McGrath, identificado como Presidente y CFO, recibió una asignación de 150.000 acciones ordinarias restringidas el 30/09/2025. Las acciones fueron otorgadas bajo el Piano de Incentivos a Largo Plazo de 2014, Sexta Enmienda y Restatement y tienen una única fecha de vesting de 20 de mayo de 2028; están sujetas a pérdidas si no se completa el periodo de servicio requerido. El Formulario 4 muestra 200.834 acciones de beneficio del responsable tras la transacción. La transacción reportada indica un precio de $0, lo que indica que se trataba de acciones restringidas en lugar de una compra en efectivo. La declaración fue ejecutada por poder y fechada el 02/10/2025.

PAVmed Inc. (PAVM) 보고자 Dennis M. McGrath사장 겸 CFO로 식별되며, 제한 주식 150,000주를 2025-09-30에 받았습니다. 이 주식은 회사의 2014년 제6차 수정된 장기 인센티브 주식계획에 따라 부여되었고 2028년 5월 20일에 단일 가주(vest) 시점을 가지며, 필요한 서비스 기간이 완료되지 않으면 몰수될 수 있습니다. Form 4는 거래 후 보고인에게 귀속되는 200,834주를 보여줍니다. 보고된 거래는 $0의 가격을 기록하여 현금 매수가 아닌 제한 주식임을 나타냅니다. 제출은 대리권으로 실행되었고 2025-10-02에 날짜가 적혀 있습니다.

PAVmed Inc. (PAVM) personne déclarante Dennis M. McGrath, identifié comme Président et CFO, a reçu une attribution de 150.000 actions ordinaires restreintes le 30/09/2025. Les actions ont été accordées en vertu du Piano d’Incentives à Long Terme 2014, Sixième Amendement et Restatement et présentent une seule date d’acquisition 20 mai 2028; elles peuvent être confisquées si la période de service requise n’est pas complétée. Le Form 4 indique que 200 834 actions sont détenues bénéficiaires par la personne déclarante après la transaction. La transaction déclarée affiche un prix de $0, indiquant qu’il s’agit d’actions restreintes plutôt que d’un achat en espèces. Le dépôt a été exécuté par procuration et daté du 02/10/2025.

PAVmed Inc. (PAVM) meldende Person Dennis M. McGrath, identifiziert als Präsident und CFO, erhielt am 30.09.2025 eine Zuteilung von 150.000 eingeschränkten Stammaktien. Die Aktien wurden gemäß dem Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan gewährt und tragen ein einziges Vesting-Datum am 20.05.2028; sie unterliegen dem Verlust, wenn der erforderliche Dienstzeitraum nicht erfüllt wird. Form 4 zeigt 200.834 Aktien, die dem meldenden Investor nach der Transaktion zustehen. Die gemeldete Transaktion listet einen Preis von $0, was darauf hindeutet, dass es sich um eingeschränkte Aktien und nicht um einen Bara kauf handelt. Die Einreichung wurde per Vollmacht ausgeführt und datiert auf den 02.10.2025.

PAVmed Inc. (PAVM) الشخص المبلغ Dennis M. McGrath، المعروف بأنه الرئيس والمدير المالي، تلقى منحة مقدارها 150,000 سهماً مقيداً في 30/09/2025. الأسهم مُنحت وفقاً لـ خطة الحوافز طويلة الأجل لعام 2014 المعدلة سادساً وإعادة صياغتها ولها تاريخ vesting واحد وهو 20 مايو 2028؛ تخضع للفقد إذا لم يُستكمل فترة الخدمة المطلوبة. يظهر النموذج 4 200,834 سهماً مستفاداً من قبل الشخص المبلغ بعد المعاملة. تقرأ المعاملة المدرجة سعر $0، مما يشير إلى أن هذه الأسهم مقيدة وليست شراء نقدي. تم تنفيذ الإبلاغ بتوكيل وتاريخ 02/10/2025.

PAVmed Inc. (PAVM) 报告人 Dennis M. McGrath,被认定为 董事长兼首席财务官,于 2025-09-30 获得了 150,000 股受限普通股的授予。此等股票依据公司 2014 年第六次修订并重述的长期激励股权计划 授予,具有单一的归属日期 2028-05-20;若未完成所需的服务期限,则可能被没收。Form 4 显示交易后报告人实际拥有的 200,834 股。所述交易显示价格为 $0,表明这是受限股而非现金购买。该申报通过授权委托执行,日期为 2025-10-02

Positive
  • 150,000 restricted shares granted with a single vesting date of May 20, 2028 supporting executive retention
  • 200,834 shares beneficially owned following the grant, indicating meaningful insider equity ownership
Negative
  • None.

Insights

TL;DR: Officer received 150,000 restricted shares vesting in May 2028, aligning pay with future service.

The grant of 150,000 restricted shares to the company’s President and CFO ties compensation to continued employment through May 20, 2028. Such time‑based restricted stock is governance‑oriented, reinforcing retention rather than immediate liquidity.

The filing reports 200,834 shares beneficially owned after the grant, which quantifies the officer’s current equity stake disclosed on the Form 4. The $0 price entry confirms these are restricted awards, not a market purchase.

PAVmed Inc. (PAVM) persona di riferimento Dennis M. McGrath, identificato come Presidente e CFO, ha ricevuto una concessione di 150.000 azioni ordinarie restritte in data 30/09/2025. Le azioni sono concesse ai sensi del Piano di Incentivi a Lungo Termine 2014, Sesto Emendamento e Restatement e hanno una data di vesting unica 20 maggio 2028; sono soggette a perdita se il periodo di servizio richiesto non è completato. Il Form 4 mostra 200.834 azioni detenute economicamente dal soggetto riportante dopo la transazione. La transazione riportata indica un prezzo di $0, il che implica che si trattava di azioni restritte anziché di un acquisto in contanti. Il deposito è stato eseguito per procura e datato 02/10/2025.

PAVmed Inc. (PAVM) persona reportante Dennis M. McGrath, identificado como Presidente y CFO, recibió una asignación de 150.000 acciones ordinarias restringidas el 30/09/2025. Las acciones fueron otorgadas bajo el Piano de Incentivos a Largo Plazo de 2014, Sexta Enmienda y Restatement y tienen una única fecha de vesting de 20 de mayo de 2028; están sujetas a pérdidas si no se completa el periodo de servicio requerido. El Formulario 4 muestra 200.834 acciones de beneficio del responsable tras la transacción. La transacción reportada indica un precio de $0, lo que indica que se trataba de acciones restringidas en lugar de una compra en efectivo. La declaración fue ejecutada por poder y fechada el 02/10/2025.

PAVmed Inc. (PAVM) 보고자 Dennis M. McGrath사장 겸 CFO로 식별되며, 제한 주식 150,000주를 2025-09-30에 받았습니다. 이 주식은 회사의 2014년 제6차 수정된 장기 인센티브 주식계획에 따라 부여되었고 2028년 5월 20일에 단일 가주(vest) 시점을 가지며, 필요한 서비스 기간이 완료되지 않으면 몰수될 수 있습니다. Form 4는 거래 후 보고인에게 귀속되는 200,834주를 보여줍니다. 보고된 거래는 $0의 가격을 기록하여 현금 매수가 아닌 제한 주식임을 나타냅니다. 제출은 대리권으로 실행되었고 2025-10-02에 날짜가 적혀 있습니다.

PAVmed Inc. (PAVM) personne déclarante Dennis M. McGrath, identifié comme Président et CFO, a reçu une attribution de 150.000 actions ordinaires restreintes le 30/09/2025. Les actions ont été accordées en vertu du Piano d’Incentives à Long Terme 2014, Sixième Amendement et Restatement et présentent une seule date d’acquisition 20 mai 2028; elles peuvent être confisquées si la période de service requise n’est pas complétée. Le Form 4 indique que 200 834 actions sont détenues bénéficiaires par la personne déclarante après la transaction. La transaction déclarée affiche un prix de $0, indiquant qu’il s’agit d’actions restreintes plutôt que d’un achat en espèces. Le dépôt a été exécuté par procuration et daté du 02/10/2025.

PAVmed Inc. (PAVM) meldende Person Dennis M. McGrath, identifiziert als Präsident und CFO, erhielt am 30.09.2025 eine Zuteilung von 150.000 eingeschränkten Stammaktien. Die Aktien wurden gemäß dem Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan gewährt und tragen ein einziges Vesting-Datum am 20.05.2028; sie unterliegen dem Verlust, wenn der erforderliche Dienstzeitraum nicht erfüllt wird. Form 4 zeigt 200.834 Aktien, die dem meldenden Investor nach der Transaktion zustehen. Die gemeldete Transaktion listet einen Preis von $0, was darauf hindeutet, dass es sich um eingeschränkte Aktien und nicht um einen Bara kauf handelt. Die Einreichung wurde per Vollmacht ausgeführt und datiert auf den 02.10.2025.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
MCGRATH DENNIS M

(Last) (First) (Middle)
360 MADISON AVENUE, 25TH FLOOR

(Street)
NEW YORK NY 10017

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PAVmed Inc. [ PAVM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President and CFO
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/30/2025 A 150,000(1) A $0(1) 200,834 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents restricted stock granted to the reporting person under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed.
/s/ Michael A. Gordon, by power of attorney 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the PAVmed (PAVM) Form 4 report?

The Form 4 reports that Dennis M. McGrath, the company’s President and CFO, was granted 150,000 restricted shares on 09/30/2025.

When do the restricted shares awarded to the PAVM officer vest?

The restricted shares have a single vesting date of May 20, 2028 and are subject to forfeiture if the service period is not completed.

How many PAVM shares does the reporting person own after the transaction?

The Form 4 shows the reporting person beneficially owns 200,834 shares following the reported transaction.

Was cash paid for the shares reported on the PAVM Form 4?

No cash was reported; the transaction lists a price of $0, indicating these were restricted stock awards.

Who signed the PAVM Form 4 filing and when?

The filing was signed by Michael A. Gordon by power of attorney on 10/02/2025.
Pavmed

NASDAQ:PAVM

PAVM Rankings

PAVM Latest News

PAVM Latest SEC Filings

PAVM Stock Data

10.65M
18.02M
18.43%
10.64%
1.15%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
NEW YORK